People: Evotec AG (EVTG.DE)

EVTG.DE on Xetra

1.98EUR
3:47am EST
Price Change (% chg)

€0.03 (+1.65%)
Prev Close
€1.94
Open
€1.98
Day's High
€1.98
Day's Low
€1.96
Volume
10,245
Avg. Vol
591,790
52-wk High
€2.45
52-wk Low
€0.54

view people for:

Summary

Name Age Since Current Position
Ornskov, Flemming 50 2008 Chairman of the Supervisory Board
Lanthaler, Werner 40 2009 Chairman of the Management Board, Chief Executive Officer
Riesenhuber, Heinz 73 2008 Honorary Chairman of the Supervisory Board
Birner, Hubert 43 2008 Vice Chairman of the Supervisory Board
Maleck, Klaus 2007 Member of the Management Board, Chief Financial Officer
Polywka, Mario 2007 Member of the Management Board, Chief Operating Officer
Gillmore, Charmion 2007 Senior Vice President Human Resources & Internal Communications
Hennecke, Anne 39 Senior Vice President, Investor Relations & Corporate Communications
Brister, David 45 2006 Chief Business Officer
Kelly, Michael 54 2008 President, Renovis, Inc. and Member of the Senior Management of Evotec
Kemp, John 55 Member of the Management Board, Chief Research & Development Officer
Tanner, Mary 57 2005 Member of the Supervisory Board
Fellner, Peter 67 2005 Member of the Supervisory Board
Goodman, Corey 57 2008 Member of the Supervisory Board
Wenninger, Walter 71 2009 Member of the Supervisory Board
» Insider Trading

Biographies

Name Description
Ornskov, Flemming Dr. Flemming Ornskov was nominated as Chairman of the Supervisory Board at Evotec AG, effective at the next Annual General Meeting on August 28, 2008. As Corporate Vice President and Global President, Pharmaceuticals, at Bausch & Lomb, he is responsible for the company's prescription and generic pharmaceuticals, as well as its general eye health and vitamins businesses. Previously, Dr. Flemming Ornskov was first Chairman, then CEO and President of LifeCycle Pharma, an emerging cardiovascular and transplantation specialty company. Prior to this, he served as CEO and President of a biotech start-up Ikaria, Inc. From 2002 to 2005, Dr. Flemming Ornskov was President of the Ophthalmics Business Unit for Novartis. Prior, he led Novartis' U.S. cardiovascular franchise. Prior to joining Novartis, Dr. Flemming Ornskov held multiple leadership positions at Merck & Co.
Lanthaler, Werner Dr. Werner Lanthaler has been Chairman of the Management Board and Chief Executive Officer at Evotec AG since March 6, 2009. Prior to joining the Company, Mr. Lanthaler has worked at Intercell AG since 2001. Before that, he served as Director of the Federation of Austrian Industry and as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master's degrees from Harvard University, and holds a degree in Psychology.
Riesenhuber, Heinz Prof. Dr. Heinz Riesenhuber was named an Honorary Chairman of the Supervisory Board at Evotec AG, effective at the next Annual General Meeting on August 28, 2008. He also serves as Chairman of the Supervisory Board at Kabel Deutschland GmbH; Member of the Supervisory Board at Frankfurter Allgemeine Zeitung GmbH and at Henkel KGaA, Düsseldorf, as well as Member of the Verwaltungsrat of HBM BioVentures AG.
Birner, Hubert Dr. Hubert Birner was Member of the Supervisory Board of Evotec AG from June 2005 till August 26, 2008, when he obtained the position of Vice Chairman of the Supervisory Board at the Company. Before he joined TVM Capital in 2000, he was Head of Business Development Europe and Director of Marketing Germany at Zeneca. Dr. Birner joined Zeneca from McKinsey & Company's European Health Care and Pharmaceutical practice. As a Management Consultant, he gained extensive experience in R&D management, marketing & sales as well as joint venture structuring and business development. Dr. Birner was also Assistant Professor for biochemistry at the Ludwig-Maximilians-University in Munich. In this capacity, he directed various research projects for large pharmaceutical companies. Dr. Birner serves as Chairman of the Supervisory Board of Direvo Biotech AG and Non-Executive Chairman of the Board of Argos Therapeutics Inc. and Spepharm Holding BV. He is also Non-Executive Board Member of BioXell SA and Member of the Supervisory Board of Jerini AG. He also represents the interests of TVM Capital at Ardana Bioscience plc and Neuro3d SA. Dr. Birner holds an MBA from Harvard Business School and a "summa cum laude" doctoral degree in biochemistry from Ludwig-Maximilians-University in Munich. His doctoral thesis was honored with the Hoffmann-La Roche prize for outstanding basic research in metabolic diseases.
Maleck, Klaus Dr. Klaus Maleck is Member of the Management Board and Chief Financial Officer of Evotec AG since November 28, 2007. Dr. Klaus Maleck has been Executive Vice President, Finance and Member of the Executive Committee of Evotec AG since April 2007. Prior to joining Evotec, he built up BioGeneriX AG, which he co-founded in 2000. In his function as Chief Financial Officer and Vice President Business Development, he was responsible for in-licensing advanced development candidates and for building a product pipeline of up to six clinical development programs and several non-clinical projects. He secured financing through extensive partnering and closed several co-marketing deals with big pharma, and thus was able to considerably increase the shareholder value. Dr. Klaus Maleck worked as Senior Consultant at McKinsey & Co. from 1999 to 2000, and as a Scientist in the genomics field at Novartis, Inc. from 1996 to 1999. He is also a lecturer at the Mannheim University in Economics. Dr. Klaus Maleck received his Ph.D. in biotechnology from the Max-Planck-Insitute Cologne, and holds a Masters degree in biotechnology from the Ecole Superieure de Biotechnologie in Strasbourg, France. In addition, he received post-graduate training in economics at Ashridge College in the UK, and at Swiss-based Educatis University, where he earned an MBA degree. He was a fellow of the Conseil Regional d'Alsace, the Daimler-Benz-Foundation and the German Scholarship Foundation.
Polywka, Mario Dr. Mario Polywka is Member of the Management Board since November 28, 2007 and Chief Operating Officer since 2004. Dr. Mario Polywka is Chief Operating Officer and has been Member of the Executive Committee of Evotec AG since 2004. Between 2002 and 2004 Dr. Mario Polywka ran a number of spin-off companies in the Oxford area, and still serves as Chairman on the boards of Pharminox and Glycoform. Following the merger of EVOTEC BioSystems AG with Oxford Asymmetry International plc (OAI) in 2000 he was Chief Operating Officer until 2002. Dr. Mario Polywka was a Founding Chemist of OAI in 1991, became Director of Chemistry in 1993 and Board Director in 1996. In 1999 he was appointed Chief Operating Officer and in 2001 Chief Executive Officer of OAI plc. From 1989 to 1991 he worked as Senior Chemist at Oxford Chirality Ltd, the forerunner to OAI. Dr. Mario Polywka received a doctorate from the University of Oxford in mechanistic organometallic chemistry and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillins. He held a number of college lectureships at Oxford University between 1988 and 1994. Dr. Mario Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.
Gillmore, Charmion Ms. Charmion Gillmore has been Senior Vice President Human Resources & Internal Communications at Evotec AG since September 2007. Prior to this, her most recent appointment was as Executive Vice President, Human Resources and Internal Communications for Mayne Pharma. She joined the Executive team to work on Mayne's transition from an Australian generics business to a London listed, oncology speciality company. She left when Mayne Pharma was acquired by Hospira Inc. in 2007. Previously, Charmion Gillmore worked for 17 years for Aventis S.A. and its legacy companies. During this time, she worked in a number of senior Human Resources (HR) roles including HR Director to the Rhone-Poulenc Rorer Discovery Center, UK Business and as HR Vice President to the global corporate functions based in the US and France. In her last role with Aventis S.A., she was based in New Jersey, US, as HR Vice President for Global Commercial Operations. She led the HR function in its support to over 100 countries and the strategic functions. Charmion Gillmore is a member of the Corporate Institute of Personnel and Development based in London.
Hennecke, Anne Ms. Anne Hennecke joined Evotec AG in 1999. She is Senior Vice President Investor Relations & Corporate Communications and Member of the Executive Committee of Evotec AG. Ms. Hennecke successfully established the Investor Relations function within Evotec and took over responsibility for the Company's corporate communications. In her role she was responsible among other things for the communication of the Initial Public Offering in 1999, the merger between Evotec Biosystems AG and Oxford Asymmetry International plc in 2000 as well as a number of public financings and the venture financing and reacquisition of Evotec Neurosciences in 2004/2005. Prior to joining Evotec she was with Schwarz Pharma AG for four years, initially in International Marketing, subsequently becoming responsible for Investor Relations and Corporate Communications. Ms. Hennecke received a diploma in pharmacy from the Heinrich-Heine-University in Dusseldorf in 1992.
Brister, David Mr. David Brister joined Evotec AG as Chief Business Officer and Member of the Executive Committee in October 2006. He brings 22 years of business experience to the Company, including 19 years in venture capital and private equity. He joined Evotec following a successful career in developing venture capital businesses at 3i and MVM. Prior to Evotec he was Director at MVM, a venture capital business focused on seed and early stage healthcare investing, where he was one of the two key executives who established the business. Prior to MVM, he was Investment Director at 3i plc and before that held sales and commercial positions with Metal Box plc. Mr. Brister holds a BSc honors degree in Genetics & Zoology from Sheffield University, UK.
Kelly, Michael Dr. Michael G Kelly has been appointed President, Renovis, Inc. and Member of the Senior Management of Evotec in May 2008, following the acquisition of Renovis by Evotec. He brings more than 26 years of pharmaceutical industry experience to the Company. From January 2006 to May 2008 he served as Senior Vice President, Research and Development, and from December 2002 to December 2005 he was Vice President, Drug Discovery of Renovis. During 2002, Dr. Kelly was Senior Director of Chemistry at NeoGenesis Pharmaceuticals, Inc., from 1999 to 2002, he worked as a Director of Research at Amgen Inc., and from 1992 to 1999, he was a Principal Scientist at Wyeth. Prior to that, from 1982 Dr Kelly was a Senior Chemist at Burroughs Wellcome. He is an inventor on more than 100 patents. Dr. Kelly received a B.S. in Chemistry from the University of Ulster, a Ph.D. in Chemistry from the University of Southampton and conducted postdoctoral research studies at the University of Michigan and the University of Nottingham.
Kemp, John Dr. John A. Kemp is Chief Research and Development Officer and Member of Evotec AG's Executive Committee. He joined the Company in July 2002 as CEO of Evotec Neurosciences GmbH (ENS). Prior to this he spent almost 20 years within the pharmaceutical industry, where he gained considerable experience in progressing projects from target initiation through to entry into the clinic. From the beginning of 2000 until joining ENS, Dr. John A. Kemp was Vice President and Head of CNS Research at Hoffmann-La Roche in Basel, Switzerland and prior to that he spent six years as Research Area Head for Neurodegenerative Diseases at Roche. Before joining Roche, Dr. John A. Kemp was at the Merck Sharp and Dohme, Neuroscience Research Centre in Harlow, UK, for almost 11 years, rising to the position of Section Leader for in vitro pharmacology. Dr. John A. Kemp trained as a Pharmacologist and Neuroscientist, obtaining his Ph.D. from the University of Southampton in 1979, and has published over 120 peer reviewed research papers in these disciplines. He is listed in the Pharmacology section of ISI's most highly cited researchers.
Tanner, Mary Ms. Mary C. Tanner has been Member of the Supervisory Board of Evotec AG since January 2005. She has devoted 22 years to the health care and consumer products industry, as Senior Managing Director at Bear Stearns and Lehman Brothers, both global investment banks. In 2004 Ms. Mary C. Tanner founded Life Sciences Partners, which specializes in healthcare investment and advisory work, following her retirement from Bear Stearns in the same year. During her 22 years at Bear Stearns and Lehman, Ms. Tanner led or supervised over 575 transactions, including 220 mergers, acquisitions and divestitures with a total disclosed value of $250+ billion. Ms. Mary C. Tanner also developed a specialization in the biotechnology industry as it emerged over the last 20 years. Ms. Mary C. Tanner received her university degree from Harvard in 1973 in philosophy and related fields. She is Non-Executive Member of the Board of Directors at Synvista Therapeutics, Inc., Montvale.
Fellner, Peter Dr. Peter Fellner has been Member of the Supervisory Board of Evotec AG since June 2005. He was appointed as Chairman of Vernalis plc in January 2003 and as Executive Chairman in April 2003. Previously, he was Chairman of Celltech Group plc, having served as its Chief Executive Officer from 1990 to 2003. He also was Non Executive Chairman of the Board of Directors at Acambis plc, Cambridge, UK until September 2008 and at Premier Research Group plc, Bracknell, UK until June 2008. Dr. Peter Fellner acted as Non Executive Member of the Board of Directors in Isis Innovation Ltd., Oxford, UK until March 2008. He holds the positions of Non Executive Chairman of the Board of Directors at Astex Therapeutics Ltd., Cambridge, UK and Non Executive Member of the Board of Directors at Consort Medical plc, Milton Keynes, UK, as well as at QinetiQ Group plc, London, UK and UCB SA, Brussels.
Goodman, Corey Dr. Corey Goodman was nominated as Member of the Supervisory Board, at Evotec AG, effective at the next Annual General Meeting on August 28, 2008. He is President of Pfizer's Biotherapeutics and Bioinnovation Center and former Chief Executive Officer & President of Renovis. He serves as None Executive Member of the Board of Directors at Limerick BioPharma, Inc South San Francisco.
Wenninger, Walter Dr. Walter Wenninger is proposed for the election as Member of the Supervisory Board of Evotec AG with effect from June 4, 2009. Dr Wenninger has experience in strategic management, research & development and sales & marketing from leading positions in the international pharmaceutical industry. His career includes more than 30 years at Bayer AG where he held top-executive management positions within the lifescience business in Europe and the United States. From 1994 to 2000, Dr. Wenninger served as a Member of the Management Board of Bayer AG with responsibility for the healthcare sector. Following his retirement at Bayer AG, he had been involved in corporate development of several life science organizations. He is Member of the Executive Committee of the German Cardiac Research Foundation, the Executive Committee of the Robert-Koch-Foundation, and was a longtime Member of the Board of Trustees of the German Cancer Research Center. Dr. Wenninger currently serves on the Boards of various other European pharmaceutical and biotechnology companies including Noxxon Pharma AG, Paion AG, Recordati S.p.A. and Santaris Pharma A/S. He holds a Masters degree in Business Administration and a Doctorate in Veterinary Medicine from Ludwig-Maximilians-Universitaet in Munich.

Basic Compensation

Name Fiscal Year Total
Ornskov, Flemming 17,900
Lanthaler, Werner --
Riesenhuber, Heinz 34,600
Birner, Hubert 32,600
Maleck, Klaus 359,000
Polywka, Mario 104,000
Gillmore, Charmion --
Hennecke, Anne --
Brister, David --
Kelly, Michael --
Kemp, John --
Tanner, Mary 26,200
Fellner, Peter 26,200
Goodman, Corey 9,000
Wenninger, Walter --
As Of 30 Dec 2008

Insider Trading

» Full list on Insider Trading
view people for: